We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Advanced Oncotherapy Plc | LSE:AVO | London | Ordinary Share | GB00BD6SX109 | ORD 25P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 1.925 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Medical Laboratories | 0 | -29.49M | -0.0549 | -0.35 | 10.32M |
From Apr 2019 to Apr 2024
TIDMAVO
RNS Number : 4275Q
Advanced Oncotherapy PLC
29 November 2016
29 November 2016
Advanced Oncotherapy plc
("Advanced Oncotherapy" or the "Company")
Director Dealing
Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it was informed yesterday that Dr Enrico Vanni, a Non-Executive Director of the Company, yesterday purchased 75,000 ordinary shares of 25 pence each in the Company ("Ordinary Shares") at an average price of 64.7 pence per Ordinary Share.
Following this transaction, Dr Vanni now holds 637,000 Ordinary Shares representing 0.88% of the issued share capital of the Company.
For further information, please contact:
Advanced Oncotherapy plc www.avoplc.com Michael Sinclair, Executive Tel: +44 20 3617 8728 Chairman Nicolas Serandour, CEO Stockdale Securities (Nomad & Joint Broker) Antonio Bossi / David Coaten Tel: +44 20 7601 6100 Stifel Nicolaus Europe (Joint Broker) Jonathan Senior / Ben Maddison Tel: +44 20 7710 7600 Walbrook PR (Financial PR Tel: +44 20 7933 8780 & IR) or avo@walbrookpr.com Paul McManus Mob: +44 7980 541 893
About Advanced Oncotherapy plc www.avoplc.com
Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM", based in Geneva, focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates greater precision and electronic control which is not achievable with older technologies.
Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.
Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCBGBDBXGDBGLC
(END) Dow Jones Newswires
November 29, 2016 05:06 ET (10:06 GMT)
1 Year Advanced Oncotherapy Chart |
1 Month Advanced Oncotherapy Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
